Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
Status
Conditions
Treatments
Details and patient eligibility
About
Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g. chronic kidney disease (CKD), metabolic complications, infections and malignancy. Everolimus (EVL) is a drug that may stabilize or improve kidney function for patients with chronic kidney disease (CKD) that has been caused by immunosuppressants. EVL is used for standard of care treatment to prevent transplant liver rejection in combination with other immunosuppressants, such as tacrolimus. The overall aim of this study is to examine a combination of two different immunosuppressants and EVL to determine if patients may have stabilized and/or improved kidney function without liver rejection. This study will look at how safe it is to slowly withdraw one anti-rejection medication while continuing to take the other medicine, and whether this can be done without liver rejection occurrence.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adult LT candidates ≥ 18 years of age
- Listed for or recent (within 1 month) recipient of deceased or living donor liver transplantation
Exclusion criteria
- Combined or previous organ transplantation
- Human immunodeficiency virus (HIV) infection
- Inability to provide informed consent or comply with the protocol.
Trial design
Primary purpose
Allocation
Interventional model
Masking
28 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal